Avenue Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $820.1K
- Price
- $0.2576
- % Change (Daily % change from the live per-ticker quote feed.)
- -8.21%
- Volume
- 2.8K
About
Avenue Therapeutics, Inc. functions as a specialized pharmaceutical enterprise, primarily dedicated to innovating and bringing to market medical therapies tailored for critical and intensive care environments within hospitals. Their leading product candidate is intravenous Tramadol, a synthetic opioid with a dual mechanism of action, currently undergoing Phase III clinical trials for the management of severe pain experienced by patients after surgery. Established in 2015, the company's operations are based in New York, New York.
Quick stats
Shares outstanding3.2M
Computed float2.8M
Float / shares89.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001644963
Websitehttps://www.avenuetx.com
AI Summary
AI-generated10d agoAvenue Therapeutics (NASDAQ:ATXI) and Collegium Pharmaceutical (NASDAQ:COLL) Head-To-Head Survey
Collegium Pharmaceutical (NASDAQ: COLL - Get Free Report) and Avenue Therapeutics (NASDAQ: ATXI - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership. Profitability This table compares Collegium Pharmaceutical and